NEW YORK, March 10, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Arrowhead Research Corp. (NASDAQ: ARWR), ANI Pharmaceuticals, Inc.
(NASDAQ: ANIP), OraSure Technologies, Inc. (NASDAQ: OSUR), Rigel
Pharmaceuticals, Inc. (NASDAQ: RIGL), and Foundation Medicine, Inc.
(NASDAQ: FMI). Private wealth members receive these notes ahead of
publication. To reserve complementary membership, limited openings
are available at: http://www.AnalystsReview.com/register
Arrowhead Research Corp. Analyst
Notes
On March 3, 2014, Arrowhead
Research Corp. (Arrowhead) announced that it has received a
regulatory approval to initiate a Phase 2a clinical trial of
ARC-520, its RNAi-based drug candidate for the treatment of chronic
hepatitis B virus (HBV) infection. According to Arrowhead, the Hong
Kong Department of Health issued a Certificate for Clinical Trial
that allows the Company to proceed with its planned single-dose
study of ARC-520 in two cohorts at two dose levels to be conducted
at Queen Mary Hospital and Prince of Wales Hospital in Hong Kong. Arrowhead reported that the site
initiation was completed and patient screening will begin shortly.
The Company added that the topline study results are expected to be
available in Q3 2014. The full analyst notes on Arrowhead Research
Corp. are available to download free of charge at:
http://www.AnalystsReview.com/03102014/ARWR/report.pdf
ANI Pharmaceuticals, Inc. Analyst
Notes
On March 5, 2014, ANI
Pharmaceuticals, Inc. (ANI) announced the pricing of a firm
commitment underwritten public offering of 1,402,525 shares of the
Company's common stock at a purchase price to the public of
$31.00 per share. ANI reported that
net proceeds to the Company are estimated to be $43.5 million, before estimated offering expenses
payable by the Company. ANI added that the offering is expected to
close on or about March 10, 2014, and
it has granted the underwriters a 30-day option to purchase up to
an additional 210,378 shares. The Company stated that it
anticipates utilizing the net proceeds of the offering to research,
develop, commercialize, and expand its drug products, to acquire
complementary businesses and technologies, and for working capital
and general corporate purposes. The full analyst notes on ANI
Pharmaceuticals, Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/03102014/ANIP/report.pdf
OraSure Technologies, Inc. Analyst
Notes
On March 5, 2014, OraSure
Technologies, Inc.'s (OraSure) stock advanced 11.37%, ending the
day at $8.23. Over the previous three
trading sessions, shares of OraSure climbed 18.58%, compared to the
Nasdaq Composite which increased 1.16% during the same period. The
full analyst notes on OraSure Technologies, Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/03102014/OSUR/report.pdf
Rigel Pharmaceuticals, Inc. Analyst
Notes
On March 4, 2014, Rigel
Pharmaceuticals, Inc. (Rigel) released its Q4 2013 and full-year
2013 results. Rigel registered quarterly revenues of $5.8 million in Q4 2013, with no comparable
revenues in Q4 2012, while annual revenues were $7.2 million in full year 2013, compared to
$2.3 million in full year 2012. The
Company posted quarterly net loss of $16.9
million or $0.19 per diluted
share, compared to net loss of $25.5
million or $0.30 per diluted
share in Q4 2012; while annual net loss came in at $89.0 million or $1.02 per diluted share, compared to net loss of
$98.8 million or $1.32 per diluted share in full year 2012.
James M. Gower, Rigel Chairman and
CEO, said, "As 2014 unfolds, Rigel has a number of significant
clinical research projects in the works, which include a good
combination of more advanced projects, such as fostamatinib in ITP,
and earlier ones, such as R118 in intermittent claudication." Gower
added, "We look forward to initiating the first of our two pivotal
P3 trials of fostamatinib in ITP next month." The full analyst
notes on Rigel Pharmaceuticals, Inc. are available to download free
of charge at:
http://www.AnalystsReview.com/03102014/RIGL/report.pdf
Foundation Medicine, Inc. Analyst
Notes
On March 5, 2014, Foundation
Medicine, Inc.'s (Foundation Medicine) stock closed at $35.53, up 7.76%. Over the previous three trading
sessions, Foundation Medicine's shares fell 0.28%, compared to the
Nasdaq Composite which rose 1.16% during the same period. The full
analyst notes on Foundation Medicine, Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/03102014/FMI/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to
leverage our economy of scale. Most investors do not have time to
track all publicly traded companies, much less perform an in-depth
review and analysis of the complexities contained in each
situation. That's where Analysts Review comes in. We provide a
single unified platform for investors' to hear about what matters.
Situation alerts, moving events, and upcoming opportunities.
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review